FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012. PMID 39806614 · BMJ Open · 2024-Dec-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma. PMID 39707376 · World J Surg Oncol · 2024-Dec-20 The record is a clinical trial protocol for a randomized comparison of irreversible electroporation (a device-based ablation technique) vs. radiofrequency ablation for hepatocellular carcinoma. It is not a drug-containing intervention. It is a protocol publication without final efficacy results, and the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation. PMID 39768701 · J Clin Med · 2024-Dec-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis. PMID 39702318 · Arthritis Res Ther · 2024-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial. PMID 39701583 · JMIR Res Protoc · 2024-Dec-19 The record is a protocol for a pilot randomized controlled trial testing an exercise intervention in multiple myeloma patients. It explicitly states it is a protocol with no results yet, the intervention is not drug-containing, and the primary endpoint is muscle strength (not a time-to-event endpoint). The phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. PMID 39694978 · J Patient Rep Outcomes · 2024-Dec-19 The report is from a phase 3, randomized, drug intervention trial in oncology, but the analyzed endpoint is a patient-reported tolerability metric, not a time-to-event efficacy outcome. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ponsegromab for the Treatment of Cancer Cachexia. PMID 39282907 · N Engl J Med · 2024-Dec-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A pilot study of a gratitude journaling intervention to enhance spiritual well-being and exercise self-efficacy in Black breast cancer survivors. PMID 39696111 · BMC Psychiatry · 2024-Dec-18 This is an oncology randomized trial in humans with original results, but it is a pilot study (not Phase III/II/III), lacks a drug intervention (gratitude journaling is a behavioral intervention), and has no time-to-event efficacy endpoint. The primary outcomes are psychosocial and biological markers, not survival or progression. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. PMID 39695887 · Adv Rheumatol · 2024-Dec-18 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Induction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial. PMID 39695871 · Trials · 2024-Dec-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials. PMID 39692806 · Discov Oncol · 2024-Dec-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL. PMID 38488491 · J Clin Endocrinol Metab · 2024-Dec-18 The trial is not an oncology study (cancer prevention in a healthy population, not a Phase II/III treatment trial for existing malignant neoplasm). The primary endpoints are functional performance measures, not a time-to-event efficacy endpoint like OS, PFS, or DFS. While the intervention includes supplements, they are not drug-based cancer therapies. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Proximal Polyps Are Associated With Higher Incidence of Colorectal Cancer: Analysis of the Minnesota Colon Cancer Control Study. PMID 39688958 · Am J Gastroenterol · 2024-Dec-17 The study is an analysis of a randomized screening trial (fecal occult-blood testing) evaluating a diagnostic/surveillance endpoint (location of adenomas and subsequent CRC risk). It does not test a drug-containing intervention. The intervention is a screening modality (fecal occult-blood test), not a therapeutic drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial. PMID 39535768 · JAMA · 2024-Dec-17 The record describes a randomized Phase III clinical trial in pediatric oncology patients. However, it is not eligible because it lacks a drug-containing intervention (the intervention is symptom screening and care pathways) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., overall survival, progression-free survival, disease-free survival, event-free survival, relapse-free survival, time to progression, Kaplan-Meier analysis, or hazard ratio). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. PMID 39676137 · Signal Transduct Target Ther · 2024-Dec-16 The record describes a Phase 2/3 trial with a drug intervention and reports time-to-event efficacy endpoints (PFS, OS). However, the eligibility criteria require explicit evidence of randomization, which is not established in the provided abstract or metadata. Therefore, the record is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life assessment in head and neck cancer: A systematic review of phase II and III clinical trials. PMID 39687101 · Heliyon · 2024-Dec-15 Systematic review of QoL endpoints in Phase II/III HNC trials; lacks drug-specific intervention and time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial. PMID 39672591 · RMD Open · 2024-Dec-12 The study is a randomized Phase 3b trial of guselkumab in psoriatic arthritis, not an oncology malignancy trial, and does not report time-to-event survival endpoints. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance. PMID 39374535 · Blood · 2024-Dec-12 The record is an original report of results from a randomized trial (RELEVANCE) in follicular lymphoma with a drug-containing intervention and a time-to-event endpoint (PFS). However, it is a biomarker-focused prognostic subgroup analysis classifying patients into molecular subtypes (MEM-like vs. GC-like) and evaluating their differential outcomes, not the primary overall trial report. The trial phase is not explicitly stated in the provided metadata, and the analysis is a subgroup analysis (prognostic biomarker-defined) rather than the primary trial result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Text message intervention delivered from Australian general practices to improve breast cancer survivors' physical activity and cardiovascular risk factors: protocol for the EMPOWER-SMS-GP effectiveness implementation randomised controlled trial. PMID 39663171 · BMJ Open · 2024-Dec-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Variability in resistance training trajectories of breast cancer patients undergoing therapy. PMID 39656317 · Support Care Cancer · 2024-Dec-10 The record describes a randomized controlled trial in oncology (breast cancer) with human participants and original results. However, it is ineligible because: 1) The intervention is purely a resistance training exercise program, lacking any drug component. 2) The primary endpoint is a measure of training progress (volume-load change), not a time-to-event efficacy endpoint like OS, PFS, DFS, or a Kaplan-Meier/HR outcome. 3) The trial phase is not specified as Phase III/IIIb or a definitive Phase II/III; the context suggests an exercise study, not a drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of mesenteric artery ligation level on patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a retrospective cohort study. PMID 39656290 · Tech Coloproctol · 2024-Dec-10 The study is a randomized trial in oncology (rectal cancer) with time-to-event endpoints (DFS, OS), but it does not involve a drug-containing intervention as the primary comparison; the comparison is surgical technique (IMA ligation level). The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Electroacupuncture promotes gastrointestinal functional recovery after radical colorectal cancer surgery: a protocol of multicenter randomized controlled trial (CORRECT trial). PMID 39652211 · Int J Colorectal Dis · 2024-Dec-09 This is a protocol for a randomized controlled trial in colorectal cancer surgery. It is an oncology, human, randomized study. However, it is explicitly a protocol without results (publication_types include 'Clinical Trial Protocol'), so it does not contain original results. The primary endpoint is time to first flatus, which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) in the context of cancer treatment efficacy. The intervention is electroacupuncture, which is a non-drug intervention. Therefore, it fails multiple criteria for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Smartphone-based distress screening, information provision, and psychotherapy for reducing psychological distress among AYA cancer survivors: protocol for a fully decentralized multicenter randomized controlled clinical trial. PMID 39193645 · Jpn J Clin Oncol · 2024-Dec-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Minimally Invasive Versus Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Trial Sequential Analysis of Randomized Trials. PMID 39682284 · Cancers (Basel) · 2024-Dec-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer. PMID 39436905 · Oncologist · 2024-Dec-06 The record describes a randomized trial in pancreatic cancer patients receiving chemotherapy, with a time-to-event analysis for CIPN. However, it does not meet the required criteria for inclusion as a definitive oncology efficacy trial because: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata; external knowledge indicates it is a Phase II trial (NCT05374876), which is excluded per protocol. 2) The primary endpoint is the incidence and time to onset of chemotherapy-induced peripheral neuropathy, which is a supportive care/safety endpoint, not a key efficacy time-to-event endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial. PMID 39631846 · J Immunother Cancer · 2024-Dec-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of erector spinae plane block and transverse abdominis plane block in postoperative recovery after laparoscopic colorectal surgery: a randomized, double-blind, controlled trial. PMID 39623446 · Perioper Med (Lond) · 2024-Dec-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Establishment of a Mesoamerican-Caribbean South-South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial. PMID 39148307 · Cancer Prev Res (Phila) · 2024-Dec-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial. PMID 39641926 · JAMA Netw Open · 2024-Dec-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Analysis of Genitourinary Rhabdomyosarcoma in Phase 3 clinical trials. PMID 39621093 · World J Urol · 2024-Dec-02 The record is a secondary pooled analysis of phase III trials, not an original result report of a single randomized trial. The drug intervention criterion is not explicitly established, as the trials are not described as evaluating a specific drug-containing intervention versus control. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma. PMID 39620432 · Cochrane Database Syst Rev · 2024-Dec-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bacillus Calmette-Guérin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau. PMID 39423450 · Vaccine · 2024-Dec-02 The trial is a randomized study of BCG vaccination for immune training in older adults, not an oncology trial. It evaluates cytokine production (immunological endpoints) as the primary outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS). The intervention is a vaccine, not a cancer drug. There is no evidence it is a Phase III/IIIb or definitive trial; it is a small (n=40) proof-of-concept study. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial on the oncologic outcomes of use of the intrauterine manipulator in the treatment of apparent uterine-confined endometrial carcinoma: the MANEC Trial. PMID 39266205 · Int J Gynecol Cancer · 2024-Dec-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The Impact of Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection on Colonic Polyp Resection and Factors Influencing Recurrence. PMID 39632425 · Surg Laparosc Endosc Percutan Tech · 2024-Dec-01 The study is a randomized controlled trial in human oncology (colonic polyps, a cancer precursor) but does not meet the core eligibility criteria. The intervention is non-drug (endoscopic procedures), and the primary efficacy endpoint is recurrence rate, not a time-to-event outcome. Phase information is not specified, and the study is not a drug intervention trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. PMID 39418029 · JAMA Oncol · 2024-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials. PMID 39352322 · Int J Radiat Oncol Biol Phys · 2024-Dec-01 The record describes a pooled analysis of methodological characteristics across multiple trials, not the formal results of a single randomized Phase III trial with a drug intervention and a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377. PMID 39320298 · Int J Radiat Oncol Biol Phys · 2024-Dec-01 This is a published erratum to a randomized phase 3 trial report. While it references a trial with oncology, human, randomized, and phase 3 characteristics, the erratum itself is not an original formal-result report of a primary/key secondary time-to-event efficacy endpoint. Additionally, no drug intervention is indicated, and no time-to-event signal is established from the available metadata. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). PMID 39180477 · J Natl Cancer Inst · 2024-Dec-01 The record describes an observational cohort study nested within a randomized trial (CALGB 80702/SWOG 80702) examining the interplay of inflammation and physical activity on disease-free survival. While the parent trial is randomized and oncology-focused, this specific publication is not a primary report of a drug intervention's efficacy. The abstract does not specify the parent trial's phase, and the study itself is an observational analysis of prognostic factors, not a Phase III drug trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial. PMID 39002849 · Int J Radiat Oncol Biol Phys · 2024-Dec-01 The record describes the initial results from a non-randomized phase I safety cohort of a phase III trial. It does not contain a drug intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report type is best classified as 'other' as it is an initial report from a trial component, not the primary analysis of the randomized phase. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. PMID 38972465 · Int J Radiat Oncol Biol Phys · 2024-Dec-01 The study is a Phase III randomized controlled trial in oncology with original results. However, it compares two radiation therapy techniques (SBPT vs. CFPT) and does not involve a drug-containing intervention. The primary endpoint (freedom from failure) is not a standard time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis as required for the cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A commentary on 'Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial'. PMID 38814288 · Int J Surg · 2024-Dec-01 This is a commentary on a phase III trial, not the original trial report itself. It lacks an abstract and does not explicitly report time-to-event efficacy results (e.g., OS, PFS, KM curves, HR) from the original trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The effect of radio-frequency ablation in treating pulmonary ground glass nodule patients and its influence on pulmonary function. PMID 40190498 · Afr Health Sci · 2024-Dec The study is a randomized controlled trial in human oncology patients, but it compares radio-frequency ablation (a procedure) to traditional surgery, not a drug-containing intervention. It does not report a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a drug-intervention randomized trial with a primary time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| After Effects of Radiation on the Caries Status of Head and Neck Cancer Patients - A Six-Month Clinical Trial. PMID 40061643 · J Pharm Bioallied Sci · 2024-Dec The study is a randomized clinical trial in oncology patients with an original result, but it is excluded because the intervention is non-drug (topical/oral preventive agents) and the primary endpoint (DMFT index) is not a time-to-event efficacy outcome (OS, PFS, DFS, EFS, RFS, TTP, KM, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analgesic Efficacy Comparison Between Ultrasound-Guided Erector Spinae Plane Block and Retrolaminar Block in Patients Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial. PMID 39835025 · Cureus · 2024-Dec Eligibility criteria not met: The study is a randomized trial in breast cancer patients, but it is not a Phase III/IIIb or Phase II/III oncology drug trial. The primary endpoint is a postoperative analgesic efficacy measure (time to rescue analgesia), not a time-to-event cancer efficacy endpoint (e.g., OS, PFS). The intervention is a regional anesthetic block, not a systemic drug therapy for cancer. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Axillary Lymph Node Dissection versus Loco-regional Radiotherapy in Management of the Axilla in Node-Negative Locally Advanced Breast Cancer Post Neoadjuvant Chemotherapy. PMID 39737822 · Chirurgia (Bucur) · 2024-Dec The study is a randomized oncology trial in humans, but it does not meet the primary eligibility criteria. It is a surgical/radiotherapy intervention study (ALND vs. ART after SLNB) with no drug-containing intervention arm (neoadjuvant chemotherapy was given to all patients pre-randomization, not as the studied intervention). The primary outcomes are loco-regional recurrence and lymphedema, which are reported as categorical percentages, not as time-to-event endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The publication does not specify a phase (e.g., Phase II/III or III), and the trial size (n=60) suggests it is likely not a definitive Phase III trial. Therefore, it lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial of Mindfulness Meditation Combined With BrainLink Intelligent Biofeedback Instrument on Pancreatic Cancer Patients Under Chemotherapy. PMID 39711061 · Brain Behav · 2024-Dec The record is an original RCT in human oncology patients with a drug intervention (chemotherapy), but it lacks explicit evidence of being a Phase III/IIIb or Phase II/III trial and does not report a primary/key time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation. PMID 39644138 · Health Technol Assess · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. PMID 39642635 · ESMO Open · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy. PMID 39642329 · JCO Clin Cancer Inform · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. PMID 39619274 · JTO Clin Res Rep · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |